FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/23/2024
Back to search
Official data from USPTO
BI-CYGNI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/23/2024
Trademark type
Word
Nice classes
5
Filing date
02/22/2022
Registration date
12/19/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/19/2023
Last transaction
12/19/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
KOVALSKY, LAURA G
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
BIVICTRIX LIMITED
Representatives
Leon R. Legleiter KDW Firm PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antibodies for medical purposes; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-infective antibiotics; anti-infective preparations; anti-infectives; anti-inflammatories; antiparasitic preparations; anti-viral agents; biological adjuvants for medical purposes; biological preparations for medical purposesnamely for the treatment of cancer; biological preparations for the treatment of cancer; biological preparations for veterinary purposes; biological diagnostic reagents for medical use; biological diagnostic reagents for veterinary use; biological tissue cultures for medical purposes; biopharmaceutical preparations for the treatment of cancer; biotechnological preparations for medical use for the treatment of cancer; blood components in the nature of blood protein fractionsblood cellular fractionsblood plasma and cord blood for medical purposes; cardiovascular pharmaceutical preparations; cardiovascular preparations; cells for medical use; cellular function activating agents for medical purposes; chemical adjuvants for medical purposes; chemical preparations for medical purposesnamely for prevention or treatment of cancer; chemical preparations for pesticidal purposespesticides; chemical preparations for pharmaceutical purposes namely for prevention or treatment of cancer; chemical preparations for testing blood for medical purposes; chemical reagents for medical use; chemical preparations for pharmaceutical usenamely for prevention or treatment of cancer; chemotherapeutics; clinical diagnostic reagents for medical use; clinical medical reagents; pharmaceutical compounds for treating cancer; pharmaceutical compounds for treating correlated pulmonary syndromes; pharmaceutical compounds for treating respiratory diseases; cord blood for medical purposes; culture media for use in treatment of cancer for medical use; cultures of microorganisms and mammalian cultures for medical use; cytostatic drugs for medical purposes; cytostatics for medical purposes; cytostatics for pharmaceutical purposes; diagnostic agents for medical use; diagnostic agents for pharmaceutical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical use; diagnostic preparations and materials in the nature of cancer diagnostics for medical purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medicinal use; diagnostic substances for medical use; diagnostic testing materials in the natural of cancer diagnostics for medical use; drugs for medical purposesnamely cancer treatment; haemostatic preparations in the nature of medical haemostatic pastehaemostatic pencils; homeopathic medicines in the nature of pharmaceuticals for use in the treatment of cancer; immunomodulators; immunostimulants; immunosuppressants for use following transplantation in the case of graft rejection; immunotherapeutic agents for bacterial infections; in vitro diagnostic preparations for medical use; living cells for medical use; living cells for veterinary use; medicinesmedicines for cancer disorders; medicines for human purposescancer medicines; medicines for intestinal disorders; medicines for the treatment of gastrointestinal diseases; medicines for treating intestinal disorders; pain relief preparations in the nature of pain relief medication; pharmaceutical compositionspreparations for the treatment of cancer; pharmaceutical drugspreparations for the treatment of cancer; pharmaceutical preparationspreparations for the treatment of cancer; pharmaceutical preparations and substancespreparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in gynecology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in the field of anesthesia; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human usepreparations for the treatment of cancer; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for medical purposespreparations for the treatment of cancer; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of allergies; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention of disorders caused by bacteria; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the prevention of disorders of the endocrine system; pharmaceutical preparations for the prevention of disorders of the genitourinary system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the musculo-skeletal system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of ocular diseases; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of diseases of the musculo-skeletal system; pharmaceutical preparations for the treatment of disorders caused by bacteria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations for the treatment of disorders of the genitourinary system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of esophagitis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for treating skeletal diseases; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating the symptoms of radiation sickness; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for use in urology; pharmaceutical preparations for veterinary use for the prevention and treatment of cancer; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals and natural remedies for the prevention and treatment of cancer; pharmacological preparations for skin care; preparations for the treatment of asthma; radioactive substances for medical purposes; radio-isotope markers for therapeutic or diagnostic use; radiological contrast substances for medical purposes; radiopharmaceutical productspharmaceutical products for the prevention and treatment of cancer; clinical medical reagents for analytical purposes; clinical reagents for veterinary or medicalanalytical purposes; clinical medical reagents for in-vitro laboratory use; clinical veterinary reagents for in-vitro laboratory use; clinical reagents for medical use; clinical medical reagents for use in diagnostic tests; clinical veterinary reagents for use in diagnostic tests; reconstituted cells for clinical treatments for skin care; reconstituted cells for medical treatments for skin care; tissue-regenerative pharmaceutical preparations; tissues for medical use in the nature of biological tissue grafts and human allograft tissue
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/28/2024
FIMP
FINAL DISPOSITION PROCESSED
03/28/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/19/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/19/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/19/2023
GPNX
NOTIFICATION PROCESSED BY IB
10/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/03/2023
PUBO
PUBLISHED FOR OPPOSITION
10/03/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/13/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/13/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/13/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/25/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
08/25/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/25/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
08/25/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/25/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/07/2023
RFNP
REFUSAL PROCESSED BY IB
02/28/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/08/2023
RFRR
REFUSAL PROCESSED BY MPU
02/07/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/13/2022
CNRT
NON-FINAL ACTION WRITTEN
12/12/2022
DOCK
ASSIGNED TO EXAMINER
12/06/2022
MAFR
APPLICATION FILING RECEIPT MAILED
09/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/01/2022
Continuous trademark protection
Get notified about every new filing that threatens BI-CYGNI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.